1. Home
  2. MNTSW vs TGTX Comparison

MNTSW vs TGTX Comparison

Compare MNTSW & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Momentus Inc. Warrant

MNTSW

Momentus Inc. Warrant

HOLD

Current Price

$0.03

Market Cap

0.0

Sector

Industrials

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$30.73

Market Cap

5.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNTSW
TGTX
Founded
N/A
1993
Country
United States
United States
Employees
123
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
5.5B
IPO Year
2019
1995

Fundamental Metrics

Financial Performance
Metric
MNTSW
TGTX
Price
$0.03
$30.73
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$54.75
AVG Volume (30 Days)
N/A
1.6M
Earning Date
N/A
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.78
Revenue
N/A
$531,898,000.00
Revenue This Year
N/A
$87.88
Revenue Next Year
N/A
$48.75
P/E Ratio
N/A
$11.16
Revenue Growth
N/A
100.88
52 Week Low
N/A
$25.28
52 Week High
N/A
$46.48

Technical Indicators

Market Signals
Indicator
MNTSW
TGTX
Relative Strength Index (RSI) 53.68 46.68
Support Level $0.02 $30.40
Resistance Level $0.05 $32.30
Average True Range (ATR) 0.01 1.13
MACD 0.00 -0.00
Stochastic Oscillator 36.27 51.75

Price Performance

Historical Comparison
MNTSW
TGTX

About MNTSW Momentus Inc. Warrant

Momentus Inc offers in-space infrastructure services by building transfer and service vehicles that carry satellites and hosted payloads between orbits in space. It is a provider of three critical functions, in the new space economy: Space Transportation, Satellite as a Service, and In-Orbit Servicing.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.

Share on Social Networks: